Within FOCUS, a comprehensive follow-up was programmed for all patients, comprising 18
domains, performed on admission, discharge, and at 3, 6, and 12 months after the event. Of …

Pulmonary embolism (PE) is the most severe clinical presentation of venous
thromboembolic disease (VTE). 1 Anticoagulant treatment is the cornerstone of its …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are used to treat acute
pulmonary embolism (PE). However, lower NOAC doses are often prescribed because of …

The purpose of this research was to identify the best course of action in response to a
diagnosis of unprovoked pulmonary embolism. This meta-review was compiled through a …

Background We aimed to describe non-compliance with guidelines and identify predictors of
non-compliance; and to evaluate the impact of non-compliance on the occurrence of clinical …

Background Guidelines recommend risk-adjusted management of pulmonary embolism
(PE). We investigated whether treatment of acute intermediate-risk PE with parenteral …

Pulmonary embolism (PE) is the third most common cardiovascular disease after myocardial
infarction and stroke, and one of the leading causes of death in Europe. Aim. Analysis of the …

This manuscript represents original work, and it is not under consideration for publication
elsewhere. It has never been neither submitted nor published in another scientific journal …

A patient with acute pulmonary embolism (PE) is a challenge to the clinician because most
treatments increase the risk for bleeding complications. Eighty percent of patients with PE …

PURPOSE: Timely anticoagulation for patients diagnosed with acute pulmonary embolism
(PE) is paramount in reducing morbidity and mortality. In fact, guidelines recommend the …